BACKGROUND: Preclinical studies demonstrated effects of drugs inhibiting the mevalonate pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the mevalonate pathway, in PC. PATIENTS AND METHODS: Prostate cancer (PC) and benign prostate tissue of 114 men who underwent radical prostatectomy were constructed to a tissue microarray. Immunohistochemical staining of FPPS was quantified by the Remmele/Stegner immunoreactivity-score. Patients' clinical follow-up was assessed. IRS was correlated to pathological and clinical data. The impact of FPPS expression on clinical course was assessed univariate and multivariate. RESULTS: Mean IRS in PC and benign tissue was 5.7 (95% CI 5.0-6.5) and 2.6 (2.1-3.0, p < 0.0001). Mean IRS in PC tissue of patients with organ-confined and locally advanced disease (pT ≥ 3) was 5.09 (4.22-5.96) and 6.87 (5.57-8.17, p = 0.035). IRS of PC tissue significantly correlated with Gleason score (p = 0.03). Patients with PC tissue IRS >3 showed shorter recurrence-free survival compared to the remaining (p = 0.01). Increased FPPS expression is an independent risk factor for early biochemical recurrence (p = 0.032). CONCLUSIONS: This is the first study on FPPS in PC specimens. The association of FPPS with established histopathological risk parameters and biochemical recurrence implicates a contribution of the mevalonate pathway to PC progression. Further functional analysis is required to explore the role of this pathway in PC and to investigate whether FPPS expression affects the response of PC cells to N-BPs.
BACKGROUND: Preclinical studies demonstrated effects of drugs inhibiting the mevalonate pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the mevalonate pathway, in PC. PATIENTS AND METHODS: Prostate cancer (PC) and benign prostate tissue of 114 men who underwent radical prostatectomy were constructed to a tissue microarray. Immunohistochemical staining of FPPS was quantified by the Remmele/Stegner immunoreactivity-score. Patients' clinical follow-up was assessed. IRS was correlated to pathological and clinical data. The impact of FPPS expression on clinical course was assessed univariate and multivariate. RESULTS: Mean IRS in PC and benign tissue was 5.7 (95% CI 5.0-6.5) and 2.6 (2.1-3.0, p < 0.0001). Mean IRS in PC tissue of patients with organ-confined and locally advanced disease (pT ≥ 3) was 5.09 (4.22-5.96) and 6.87 (5.57-8.17, p = 0.035). IRS of PC tissue significantly correlated with Gleason score (p = 0.03). Patients with PC tissue IRS >3 showed shorter recurrence-free survival compared to the remaining (p = 0.01). Increased FPPS expression is an independent risk factor for early biochemical recurrence (p = 0.032). CONCLUSIONS: This is the first study on FPPS in PC specimens. The association of FPPS with established histopathological risk parameters and biochemical recurrence implicates a contribution of the mevalonate pathway to PC progression. Further functional analysis is required to explore the role of this pathway in PC and to investigate whether FPPS expression affects the response of PC cells to N-BPs.
Authors: A S Merseburger; A G Anastasiadis; J Hennenlotter; D Schilling; P Simon; S A Machtens; J Serth; A Stenzl; M A Kuczyk Journal: World J Urol Date: 2006-08-09 Impact factor: 4.226
Authors: Robert J Hamilton; Lionel L Banez; William J Aronson; Martha K Terris; Elizabeth A Platz; Christopher J Kane; Joseph C Presti; Christopher L Amling; Stephen J Freedland Journal: Cancer Date: 2010-07-15 Impact factor: 6.860
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Hans-Peter Schmid; Theo Van der Kwast; Thomas Wiegel; Filiberto Zattoni; Axel Heidenreich Journal: Eur Urol Date: 2011-01-25 Impact factor: 20.096
Authors: Monica Marra; Giuseppina Salzano; Carlo Leonetti; Pierfrancesco Tassone; Marco Scarsella; Silvia Zappavigna; Teresa Calimeri; Renato Franco; Giuseppina Liguori; Giovanni Cigliana; Roberta Ascani; Maria Immacolata La Rotonda; Alberto Abbruzzese; Pierosandro Tagliaferri; Michele Caraglia; Giuseppe De Rosa Journal: Nanomedicine Date: 2011-03-29 Impact factor: 5.307
Authors: Qi Long; Jianpeng Xu; Adeboye O Osunkoya; Soma Sannigrahi; Brent A Johnson; Wei Zhou; Theresa Gillespie; Jong Y Park; Robert K Nam; Linda Sugar; Aleksandra Stanimirovic; Arun K Seth; John A Petros; Carlos S Moreno Journal: Cancer Res Date: 2014-04-08 Impact factor: 12.701
Authors: Joseph Longo; Stephen J Freedland; Linda Z Penn; Robert J Hamilton Journal: Prostate Cancer Prostatic Dis Date: 2022-06-29 Impact factor: 5.554
Authors: Simona Pisanti; Erika Rimondi; Elena Pozza; Elisabetta Melloni; Enrico Zauli; Maurizio Bifulco; Rosanna Martinelli; Annalisa Marcuzzi Journal: Int J Environ Res Public Health Date: 2022-07-25 Impact factor: 4.614
Authors: Ruth Soler-Agesta; Joaquín Marco-Brualla; Martha Minjárez-Sáenz; Christina Y Yim; Marta Martínez-Júlvez; Matthew R Price; Raquel Moreno-Loshuertos; Tyler D Ames; José Jimeno; Alberto Anel Journal: Cancers (Basel) Date: 2022-08-09 Impact factor: 6.575